Vimian Group AB
STO:VIMIAN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.7617
46.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Vimian Group AB
Cost of Revenue
Vimian Group AB
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Vimian Group AB
STO:VIMIAN
|
Cost of Revenue
-€187.2m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
OssDsign AB
STO:OSSD
|
Cost of Revenue
-kr28.5m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Cost of Revenue
-kr192.1m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-26%
|
|
|
D
|
Doxa AB
STO:DOXA
|
Cost of Revenue
-kr5.1m
|
CAGR 3-Years
23%
|
CAGR 5-Years
25%
|
CAGR 10-Years
12%
|
|
|
Bactiguard Holding AB
STO:BACTI B
|
Cost of Revenue
-kr161.9m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
S
|
S2Medical AB (publ)
STO:S2M
|
Cost of Revenue
-kr1.1m
|
CAGR 3-Years
39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vimian Group AB
Glance View
Vimian Group AB operates as an animal health company. The company is headquartered in Stockholm, Stockholm and currently employs 1,068 full-time employees. The company went IPO on 2021-06-18. The firm is a parent company of the group of companies operating with a purpose of improving animal health through science and technology. The Group delivers solutions to veterinary professionals, labs and pet parents around the world. The purpose of Vimian Group is to unite companies in selected niches of animal health and help them grow faster. The firm invests in innovation and new technologies to advance veterinary medicine. The Group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to its networks, advisory services, infrastructure and capital.
See Also
What is Vimian Group AB's Cost of Revenue?
Cost of Revenue
-187.2m
EUR
Based on the financial report for Sep 30, 2024, Vimian Group AB's Cost of Revenue amounts to -187.2m EUR.
What is Vimian Group AB's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-60%
Over the last year, the Cost of Revenue growth was -43%. The average annual Cost of Revenue growth rates for Vimian Group AB have been -60% over the past three years .
You don't have any saved screeners yet
